Cargando…
Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction
Chimeric antigen receptor (CAR) T-cell therapy is a promising and rapidly expanding therapeutic option for a wide range of human malignancies. Despite the ongoing progress of CAR T-cell therapy in hematologic malignancies, the application of this therapeutic strategy in solid tumors has encountered...
Autores principales: | Mardi, Amirhossein, Shirokova, Anastasia V., Mohammed, Rebar N., Keshavarz, Ali, Zekiy, Angelina O., Thangavelu, Lakshmi, Mohamad, Talar Ahmad Merza, Marofi, Faroogh, Shomali, Navid, Zamani, Amir, Akbari, Morteza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052538/ https://www.ncbi.nlm.nih.gov/pubmed/35488303 http://dx.doi.org/10.1186/s12935-022-02585-z |
Ejemplares similares
-
Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
por: Marofi, Faroogh, et al.
Publicado: (2021) -
A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19)
por: Mohammed, Rebar N., et al.
Publicado: (2022) -
Correction to: A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19)
por: Mohammed, Rebar N., et al.
Publicado: (2022) -
Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances
por: Nikoo, Marzieh, et al.
Publicado: (2022) -
Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism
por: Marofi, Faroogh, et al.
Publicado: (2021)